×
About 1,317 results

ALLMedicine™ Primary CNS Lymphoma Center

Research & Reviews  647 results

Successful treatment of EBV-associated Primary CNS Lymphoma due to PTLD, with Ibrutinib...
https://doi.org/10.1111/ajt.16628
American Journal of Transplantation : Official Journal Of... Law SC, Hoang T et. al.

May 4th, 2021 - Primary central nervous system lymphoma (PCNSL) occurring following organ transplantation (post-transplantation lymphoproliferative disorder 'PTLD') is a highly aggressive non-Hodgkin lymphoma. It is typically treated with high-dose methotrexate-b...

Sorting biologic subtypes of primary CNS lymphoma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976509
Blood Roschewski M, Phelan JD

Mar 18th, 2021 - Sorting biologic subtypes of primary CNS lymphoma.|2021|Roschewski M,Phelan JD,|

Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: res...
https://doi.org/10.1093/neuonc/noab021
Neuro-oncology van der Meulen M, Dirven L et. al.

Feb 9th, 2021 - To analyze the effect of treatment on neurocognitive functioning and the association of neurocognition with radiological abnormalities in primary central nervous system lymphoma (PCNSL). 199 patients from a phase III trial (HOVON 105/ALLG NHL 24),...

Consensus Recommendations for MRI and PET Imaging of Primary Central Nervous System Lym...
https://doi.org/10.1093/neuonc/noab020
Neuro-oncology Barajas RF, Politi LS et. al.

Feb 9th, 2021 - Advanced molecular and pathophysiologic characterization of Primary Central Nervous System Lymphoma (PCNSL) has revealed insights into promising targeted therapeutic approaches. Medical imaging plays a fundamental role in PCNSL diagnosis, staging,...

Exome sequencing identifies SLIT2 variants in primary CNS lymphoma.
https://doi.org/10.1111/bjh.17319
British Journal of Haematology; Kaulen LD, Erson-Omay EZ et. al.

Jan 22nd, 2021 - SLIT2 constitutes a known tumour suppressor gene, which has not yet been implicated in the pathogenesis of primary central nervous system lymphoma (PCNSL). Performing exome sequencing on paired blood and tumour DNA samples from six treatment-naïve...

see more →

Clinicaltrials.gov  659 results

Successful treatment of EBV-associated Primary CNS Lymphoma due to PTLD, with Ibrutinib...
https://doi.org/10.1111/ajt.16628
American Journal of Transplantation : Official Journal Of... Law SC, Hoang T et. al.

May 4th, 2021 - Primary central nervous system lymphoma (PCNSL) occurring following organ transplantation (post-transplantation lymphoproliferative disorder 'PTLD') is a highly aggressive non-Hodgkin lymphoma. It is typically treated with high-dose methotrexate-b...

Sorting biologic subtypes of primary CNS lymphoma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976509
Blood Roschewski M, Phelan JD

Mar 18th, 2021 - Sorting biologic subtypes of primary CNS lymphoma.|2021|Roschewski M,Phelan JD,|

Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: res...
https://doi.org/10.1093/neuonc/noab021
Neuro-oncology van der Meulen M, Dirven L et. al.

Feb 9th, 2021 - To analyze the effect of treatment on neurocognitive functioning and the association of neurocognition with radiological abnormalities in primary central nervous system lymphoma (PCNSL). 199 patients from a phase III trial (HOVON 105/ALLG NHL 24),...

Consensus Recommendations for MRI and PET Imaging of Primary Central Nervous System Lym...
https://doi.org/10.1093/neuonc/noab020
Neuro-oncology Barajas RF, Politi LS et. al.

Feb 9th, 2021 - Advanced molecular and pathophysiologic characterization of Primary Central Nervous System Lymphoma (PCNSL) has revealed insights into promising targeted therapeutic approaches. Medical imaging plays a fundamental role in PCNSL diagnosis, staging,...

Exome sequencing identifies SLIT2 variants in primary CNS lymphoma.
https://doi.org/10.1111/bjh.17319
British Journal of Haematology; Kaulen LD, Erson-Omay EZ et. al.

Jan 22nd, 2021 - SLIT2 constitutes a known tumour suppressor gene, which has not yet been implicated in the pathogenesis of primary central nervous system lymphoma (PCNSL). Performing exome sequencing on paired blood and tumour DNA samples from six treatment-naïve...

see more →

News  11 results

Primary CNS lymphoma: R-CHOP hits back
https://www.mdedge.com/hematology-oncology/article/210341/b-cell-lymphoma/primary-cns-lymphoma-r-chop-hits-back?channel=59374
Vanja Zeremski, MD, Thomas Fischer, MD

Oct 17th, 2019 - Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of non-Hodgkin lymphoma solely confined to the CNS. The majority of PCNSL histologically presents as diffuse large B-cell lymphoma (DLBCL).

Rituximab boosts survival in primary CNS lymphoma
https://www.mdedge.com/hematology-oncology/article/197142/b-cell-lymphoma/rituximab-boosts-survival-primary-cns-lymphoma?channel=59374
Will Pass

Mar 22nd, 2019 - For patients with primary central nervous system lymphoma (PCNSL), adding rituximab to combination high-dose methotrexate and temozolomide significantly boosted the 5-year overall survival rate, according to a retrospective study. The triplet comb.

AUDIO: Immunotherapy’s role in NHL
https://www.mdedge.com/hematologynews/nhlhub/article/156128/aggressive-lymphomas/audio-immunotherapys-role-nhl
Mary Ellen Schneider

Jan 11th, 2018 - ATLANTA – The use of immune checkpoint blockade is increasingly becoming standard therapy in Hodgkin lymphoma, but this approach has so far garnered mixed results in non-Hodgkin lymphoma, Stephen Ansell, MD, PhD, said at the annual meeting of the.

Serious AEs reported too late in lymphoma trial
https://www.mdedge.com/hematology-oncology/article/188810/lymphoma-plasma-cell-disorders/serious-aes-reported-too-late-lymphoma-trial
HT Staff

Oct 24th, 2016 - NIH Director Francis Collins Photo by Bill Branson Investigators conducting a phase 1 trial failed to follow requirements for reporting serious adverse events (AEs), including deaths, according to officials from the National Cancer Institute (NCI).

Temsirolimus results in good but short-duration responses in primary CNS lymphoma
https://www.mdedge.com/neurology/article/107329/aggressive-lymphomas/temsirolimus-results-good-short-duration-responses
Neil Osterweil

Mar 14th, 2016 - Single-agent therapy with temsirolimus was active in patients with relapsed/refractory primary central nervous system lymphoma, but most of the responses were short lived, results of a phase II trial show. Among 37 patients with primary CNS lympho.

see more →